• Explore /
  • Poster
  • / CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.

CXCR4 antagonist (BL-8040) to enhance antitumor effects by increasing tumor infiltration of antigen-specific effector T-cells.

Abstract Poster

Authors

null

Pankaj Gaur

Georgia Cancer Center, Augusta, GA

Pankaj Gaur, Vivek Verma, Seema Gupta, Ella Sorani, Abi Vainstein Haras, Galia Oberkovitz, Amnon Peled, Samir Khleif

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Vaccines and Oncolytic Viruses

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 73)

DOI

10.1200/JCO.2018.36.5_suppl.73

Abstract #

73

Poster Bd #

E9

Abstract Disclosures

Similar Posters

Poster

2014 Genitourinary Cancers Symposium

Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.

Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.

First Author: Ravi Amrit Madan

First Author: Neil Lorne Berinstein

First Author: Yang Zhang

First Author: Sofie Kirial Mørk